Do tumors detected by mammography screening have a favorable prognosis?

JAMA

Volumn 292, Issue 9, 2004, Pages 1062-1063

  O'Regan, Ruth M ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER SURVIVAL; EARLY DIAGNOSIS; EDITORIAL; HUMAN; LYMPH NODE METASTASIS; MAMMOGRAPHY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING; TUMOR VOLUME;

EID: 4344674096     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.9.1062     Document Type: Editorial

References (16)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
2. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer [published correction appears in Lancet. 2002;360:1520]. Lancet. 2002;359:2131-2139.
3. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer [published correction appears in Lancet. 2002;360:1520]. Lancet. 2002;359:2131-2139.
4. Coombes RC, Hall E, Gibson U, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
5. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
6. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer. Lancet. 1998;352:930-942.
7. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights. J Clin Oncol. 2003;21:3357-3365.
8. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement. J Natl Cancer Inst 2001;93:979-989.
9. Moody-Ayers SY, Wells CK, Feinstein AR. "Benign" tumors and "early detection" in mammography-screened patients of a natural cohort with breast cancer. Arch Intern Med. 2000;160:1109-1115.
10. Klemi PJ, Parvinen I, Pylkkanen L, et al. Significant improvement in breast cancer survival through population-based mammography screening. Breast. 2003;12:308-313.
11. Porter PL, El-Bastawissi AY, Mandelson MT, et al. Breast tumor characteristics as predictors of mammographic detection. J Natl Cancer Inst. 1999;91:2020-2028.
12. Joensuu H, Lehtimaki T, Holli K, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA. 2004;292:1064-1073.
13. Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001;93:112-120.
14. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980-991.
15. Paik S, Shak S, Tang G, et al. Multi-gene RT-PCR assay for predicting recurrence in node-negative breast cancer patients. Breast Cancer Res Treat. 2003;82 (abstract 16):S10.
16. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427-437.